Skip to main content
. 2019 Jul 8;11(8):e10409. doi: 10.15252/emmm.201910409

Figure 8. Role of MsrB2 in Parkinson's disease platelets.

Figure 8

  • A
    Representative Western blot analysis of MsrB2, LC3I/II, and Parkin using Parkinson's disease (PD) platelets. Quantification analysis of individual band intensity (MsrB2, *P = 0.0255; LC3II, *P = 0.0101 vs. HC (= 5) and PD (n = 12)). GAPDH served as the loading control (mean ± SD).
  • B
    Platelet apoptosis (Annexin V) was measured by flow cytometry analysis in HC (= 9) and PD (= 13) platelets (**P < 0.01 vs. HC) (mean ± SD).
Data information: The nonparametric t‐test was performed for comparisons of two groups. Analysis was performed with Prism software (GraphPad Software, Inc., La Jolla, CA). A difference of < 0.05 was considered significant.